CLEVELAND, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company is scheduled to present at the Lazard Capital Markets Seventh Annual Healthcare Conference, being held November 16 and 17, 2010 at the St. Regis Hotel in New York City.
Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will provide a corporate and product overview of the Company on Wednesday, November 17, 2010 at 2:15 pm EST. Investors may listen to a live audio web cast of Athersys' presentation by accessing the following link: http://www.wsw.com/webcast/lz8/athx/ . A web cast replay of the presentation can be accessed via the Company's web site at www.athersys.com, under the "Investors Section."
About AthersysAthersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem ®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE ®). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com. The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548
CONTACT: Athersys, Inc. William (B.J.) Lehmann, J.D., President and COO (216) 431-9900 firstname.lastname@example.org In-Site Communications Investor Relations: Lisa M. Wilson (917) 543-9932 email@example.com Pure Communications, Inc. Media Relations: Dan Budwick (973) 271-6085 firstname.lastname@example.org